We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
(-0.32%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$60.5M |
| 2 |
S&P Global
SPGI
|
+$52.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$41.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$38.2M |
| 5 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$98.3M |
| 2 |
Eli Lilly
LLY
|
+$54.1M |
| 3 |
Apple
AAPL
|
+$51.2M |
| 4 |
Fidelity National Information Services
FIS
|
+$42.9M |
| 5 |
Stryker
SYK
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Financials | 21.66% |
| 3 | Technology | 21.39% |
| 4 | Communication Services | 9.45% |
| 5 | Consumer Discretionary | 5.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
Y
51
DELISTED
Alleghany Corp
Y
| $30.2M | 0.57% |
55,000
| – | – |
|
52
Oracle
ORCL
$331B
| $29.1M | 0.55% |
709,912
-272,313
| -28% | -$10.9M |
|
|
WCN
53
Waste Connections
WCN
$42.8B
| $29M | 0.55% |
603,566
-209,116
| -26% | -$9.51M |
|
54
Incyte
INCY
$23.5B
| $28.8M | 0.54% |
360,711
+23,842
| +7% | +$1.85M |
|
55
Labcorp
LH
$24.3B
| $28.8M | 0.54% |
+256,984
| New | +$27.7M |
|
56
Methanex
MEOH
$4.32B
| $28.6M | 0.54% |
981,603
+443,162
| +82% | +$14.2M |
|
|
ATVI
57
DELISTED
Activision Blizzard
ATVI
| $28.3M | 0.53% |
713,321
+159,370
| +29% | +$5.85M |
|
58
Baxter International
BAX
$11.6B
| $28M | 0.53% |
+620,000
| New | +$27.2M |
|
59
Carnival Corporation Ltd
CCL
$36.1B
| $27.7M | 0.52% |
627,247
-159,542
| -20% | -$7.82M |
|
|
60
Fidelity National Information Services
FIS
$21.5B
| $27.7M | 0.52% |
375,488
-609,643
| -62% | -$42.9M |
|
|
ZEN
61
DELISTED
ZENDESK INC
ZEN
| $27.2M | 0.51% |
1,030,153
+126,656
| +14% | +$3.06M |
|
62
Dolby
DLB
$4.72B
| $27.1M | 0.51% |
565,762
+98,012
| +21% | +$4.48M |
|
|
WBA
63
DELISTED
Walgreens Boots Alliance
WBA
| $26.6M | 0.5% |
320,000
+82,000
| +34% | +$6.62M |
|
64
Micron Technology
MU
$1.04T
| $26.4M | 0.5% |
1,916,157
+73,750
| +4% | +$838K |
|
65
8x8 Inc
EGHT
$247M
| $26.3M | 0.5% |
1,799,078
-310,871
| -15% | -$3.81M |
|
66
TripAdvisor
TRIP
$1.59B
| $26.2M | 0.49% |
407,100
+98,827
| +32% | +$6.41M |
|
67
TE Connectivity
TEL
$58.8B
| $25.8M | 0.49% |
450,905
-368,771
| -45% | -$22.2M |
|
68
Jazz Pharmaceuticals
JAZZ
$15.9B
| $25.6M | 0.48% |
+180,885
| New | +$26.7M |
|
69
Electronic Arts
EA
$52.4B
| $24.8M | 0.47% |
328,438
-41,446
| -11% | -$2.92M |
|
70
HCA Healthcare
HCA
$84.8B
| $24.7M | 0.47% |
321,027
| – | – |
|
|
ABMD
71
DELISTED
Abiomed Inc
ABMD
| $23.8M | 0.45% |
218,000
| – | – |
|
72
Adobe
ADBE
$89.5B
| $23.7M | 0.45% |
247,226
+147,249
| +147% | +$14.1M |
|
73
Merck
MRK
$324B
| $23.6M | 0.45% |
429,680
| – | – |
|
74
BioMarin Pharmaceuticals
BMRN
$11.5B
| $23.5M | 0.44% |
301,655
-49,527
| -14% | -$4.21M |
|
75
AGCO
AGCO
$8.78B
| $23.3M | 0.44% |
493,480
-350
| -0.1% | -$18K |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.
- Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
- Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
- Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
- Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
- Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
- Polar Capital opened 35 new positions and closed 35 in Q2 2016.
- Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.
Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.